EyeGene Inc (185490) - Net Assets

Latest as of March 2026: ₩50.92 Billion KRW ≈ $34.51 Million USD

Based on the latest financial reports, EyeGene Inc (185490) has net assets worth ₩50.92 Billion KRW (≈ $34.51 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩64.70 Billion ≈ $43.85 Million USD) and total liabilities (₩13.78 Billion ≈ $9.34 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check EyeGene Inc tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩50.92 Billion
% of Total Assets	78.7%
Annual Growth Rate	27.18%
5-Year Change	-39.02%
10-Year Change	235.2%
Growth Volatility	213.76

EyeGene Inc - Net Assets Trend (2014–2025)

This chart illustrates how EyeGene Inc's net assets have evolved over time, based on quarterly financial data. See EyeGene Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for EyeGene Inc (2014–2025)

The table below shows the annual net assets of EyeGene Inc from 2014 to 2025. For live valuation and market cap data, see market cap of EyeGene Inc.

Year	Net Assets	Change
2025-12-31	₩54.25 Billion ≈ $36.77 Million	+7.81%
2024-12-31	₩50.32 Billion ≈ $34.10 Million	-21.78%
2023-12-31	₩64.33 Billion ≈ $43.60 Million	-3.59%
2022-12-31	₩66.73 Billion ≈ $45.22 Million	-25.00%
2021-12-31	₩88.97 Billion ≈ $60.29 Million	+589.72%
2020-12-31	₩12.90 Billion ≈ $8.74 Million	-32.22%
2019-12-31	₩19.03 Billion ≈ $12.90 Million	-18.48%
2018-12-31	₩23.34 Billion ≈ $15.82 Million	-1.72%
2017-12-31	₩23.75 Billion ≈ $16.10 Million	+46.76%
2016-12-31	₩16.19 Billion ≈ $10.97 Million	-28.90%
2015-12-31	₩22.76 Billion ≈ $15.43 Million	+490.68%
2014-12-31	₩3.85 Billion ≈ $2.61 Million	--

Equity Component Analysis

This analysis shows how different components contribute to EyeGene Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 16067449255000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Other Components	₩234.59 Billion	410.65%
Total Equity	₩57.13 Billion	100.00%

EyeGene Inc Competitors by Market Cap

The table below lists competitors of EyeGene Inc ranked by their market capitalization.

Company	Market Cap
Australian Mines Ltd AU:AUZ	$29.03 Million
Eastern Commercial Leasing Public Company Limited BK:ECL	$29.03 Million
BPL Limited NSE:BPL	$29.05 Million
Energía Innovación y Desarrollo Fotovoltaico S.A. MC:EIDF	$29.05 Million
FingerMotion Inc NASDAQ:FNGR	$29.02 Million
ENERGIA IN.Y DES. EO 025 F:F63	$29.02 Million
Xali Gold Corp V:XGC	$29.01 Million
Lotus KFM Bhd KLSE:8303	$29.00 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in EyeGene Inc's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 50,321,061,750 to 57,127,254,790, a change of 6,806,193,040 (13.5%).
Net loss of 15,706,096,860 reduced equity.
New share issuances of 22,115,223,920 increased equity.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	₩-15.71 Billion	-27.49%
Share Issuances	₩22.12 Billion	+38.71%
Other Changes	₩397.07 Million	+0.7%
Total Change	₩-	13.53%

Book Value vs Market Value Analysis

This analysis compares EyeGene Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.75x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 1.14x to 0.75x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	₩1231.29	₩1406.00	x
2017-12-31	₩1653.90	₩1406.00	x
2018-12-31	₩1621.25	₩1406.00	x
2019-12-31	₩1264.79	₩1406.00	x
2020-12-31	₩845.51	₩1406.00	x
2021-12-31	₩4155.60	₩1406.00	x
2022-12-31	₩3106.77	₩1406.00	x
2023-12-31	₩2339.28	₩1406.00	x
2024-12-31	₩1861.69	₩1406.00	x
2025-12-31	₩1875.15	₩1406.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently EyeGene Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -27.49%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -440.34%
• Asset Turnover: 0.05x
• Equity Multiplier: 1.19x
Recent ROE (-27.49%) is above the historical average (-44.44%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2014	-75.92%	-1902.44%	0.03x	1.44x	₩-3.31 Billion
2015	-21.51%	-4552.80%	0.00x	1.07x	₩-7.17 Billion
2016	-51.10%	-3094.59%	0.01x	1.15x	₩-9.89 Billion
2017	-35.58%	-2807.29%	0.01x	1.27x	₩-10.83 Billion
2018	-25.31%	-290.27%	0.04x	2.32x	₩-8.24 Billion
2019	-45.93%	-205.88%	0.09x	2.49x	₩-10.64 Billion
2020	-115.22%	-441.90%	0.08x	3.44x	₩-16.15 Billion
2021	-38.85%	-1066.25%	0.03x	1.18x	₩-43.47 Billion
2022	-38.89%	-490.29%	0.07x	1.20x	₩-32.63 Billion
2023	-33.38%	-675.30%	0.04x	1.24x	₩-27.43 Billion
2024	-24.10%	-361.41%	0.05x	1.30x	₩-17.16 Billion
2025	-27.49%	-440.34%	0.05x	1.19x	₩-21.42 Billion

Industry Comparison

This section compares EyeGene Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $404,884,724,361
Average return on equity (ROE) among peers: -5.25%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
EyeGene Inc (185490)	₩50.92 Billion	-75.92%	0.27x	$29.03 Million
ORIENTBIO Inc. (002630)	$44.21 Billion	0.00%	0.54x	$72.49 Million
Green Cross (005250)	$1.85 Trillion	1.30%	0.98x	$342.58 Million
Green Cross Holdings Preference Shares (005257)	$1.88 Trillion	-2.88%	0.99x	$3.26 Million
Pharmicell (005690)	$86.44 Billion	7.32%	0.15x	$579.46 Million
GeneOne Life Science Inc (011000)	$29.41 Billion	-40.45%	0.68x	$51.80 Million
HLB Co. Ltd (028300)	$18.60 Billion	0.00%	1.06x	$4.45 Billion
Daesung Microbiological Labs. Co. Ltd (036480)	$36.31 Billion	4.18%	0.71x	$16.87 Million
Seoulin Bioscience Co.Ltd (038070)	$45.30 Billion	4.03%	0.46x	$30.03 Million
Hyundai Bioscience Co. Ltd (048410)	$24.60 Billion	2.89%	0.76x	$598.77 Million
iNtRON Biotechnology Inc (048530)	$30.24 Billion	-28.88%	0.51x	$59.56 Million

About EyeGene Inc

KQ:185490 Korea Biotechnology

Market Cap

$29.03 Million

₩42.83 Billion KRW

Market Cap Rank

#23926 Global

#1646 in Korea

Share Price

₩1406.00

Change (1 day)

+0.07%

52-Week Range

₩1193.00 - ₩3630.00

All Time High

₩50300.00